SUMY STATE UNIVERSITY, SUMY, UKRAINE.
SUMY LASER CLINIC, SUMY, UKRAINE.
Wiad Lek. 2021;74(8):1921-1924.
The aim: The study was aimed to compare the efficiency of intrathyroid steroid injection to oral steroid intake in patients with subacute thyroiditis.
Materials and methods: 32 patients with subacute thyroiditis with insufficient result from NSAIDs treatment were randomly divided into two groups. The 1st group received two intrathyroid steroid injections, the 2nd group received oral prednisone. The results of the treatment were evaluated via ultrasound and evaluation of ESR and CRP at 0, 2, 4, 8 and 16 weeks of treatment.
Results: Patients of the 1st group showed much faster result at the ultrasound compared to the 2nd group: mean decrease in hypoechogenity area 44,42% vs 16,35% at week 2, p < 0,001; 93,29% vs 75,98% at week 4, p < 0,001; 97,8% vs 95,24% at week 8, p = 0,4; mean decrease in ESR 66,34% vs 51,92% at week 2, p = 0,023; 84,43% vs 74,94% at week 4, p = 0,023; mean decrease in CRP 26,53% vs 20,77% at week 2, p = 0,024, 33,77% vs 29,98%, at week 4, p = 0,026. No side effects were noted during the treatment of patients of the 1st group.
Conclusions: Compared to oral steroid intake intrathyroid steroid injection is faster, safer and generally better tolerated by patients.
本研究旨在比较甲状腺内类固醇注射与口服类固醇治疗亚急性甲状腺炎的疗效。
32 例 NSAIDs 治疗效果不佳的亚急性甲状腺炎患者随机分为两组。第 1 组接受两次甲状腺内类固醇注射，第 2 组接受口服泼尼松。通过超声和治疗后 0、2、4、8 和 16 周时 ESR 和 CRP 的评估来评价治疗结果。
第 1 组患者的超声结果显示出更快的疗效：第 2 周时低回声区域的平均减少率分别为 44.42%和 16.35%，p<0.001；第 4 周时分别为 93.29%和 75.98%，p<0.001；第 8 周时分别为 97.8%和 95.24%，p=0.4；第 2 周时 ESR 的平均减少率分别为 66.34%和 51.92%，p=0.023；第 4 周时分别为 84.43%和 74.94%，p=0.023；第 2 周时 CRP 的平均减少率分别为 26.53%和 20.77%，p=0.024；第 4 周时分别为 33.77%和 29.98%，p=0.026。第 1 组患者在治疗过程中未出现不良反应。
与口服类固醇治疗相比，甲状腺内类固醇注射起效更快、安全性更高，且患者普遍耐受更好。
